BERLIN / LONDON (IT BOLTWISE) – The supply of children’s medicines in Germany has stabilized, but shortages remain for critical drugs such as antibiotics and cancer drugs. Despite political measures, European manufacturers are often at a disadvantage when it comes to tendering, which increases their dependence on Asia.

Today’s daily deals at Amazon! ˗ˋˏ$ˎˊ˗

The supply of children’s medicines in Germany is showing a slight improvement, but the challenges remain. The pharmaceutical association Pro Generika emphasizes that despite political measures such as the Act to Combat Supply Bottlenecks, bottlenecks in supply-critical medications have increased. Antibiotics and outpatient cancer medications are particularly affected, and their availability remains limited.

A central problem is the dependence on Asian manufacturers, particularly from China and India. European producers only receive contracts for around half of the active ingredients in tenders, which endangers security of supply. Investments in the expansion or construction of new production facilities in Europe have so far failed to materialize, which further exacerbates the situation.

The anti-supply shortage law introduced in the summer of 2023 was intended to improve the situation by relaxing price rules for children’s medicines and requiring larger stocks. According to an analysis by the Berlin research institute Iges, this has led to a reduction in bottlenecks, at least for children’s medicines. However, dependence on a few manufacturers remains a risk, as 60 percent of children’s medicines are only produced by a single supplier.

Pro Generics is therefore calling for further relief, including for medicines that are critical to the supply. The cost pressure caused by price regulation is cited as the main reason why some manufacturers are withdrawing from production. The rising production costs cannot be passed on to customers, which reduces the economic attractiveness of production in Germany. A sustainable solution therefore requires not only short-term measures, but also long-term investments in European production capacity.


Order an Amazon credit card without an annual fee with a credit limit of 2,000 euros!




Bestseller No. 1 ᵃ⤻ᶻ “KI Gadgets”

Bestseller No. 2 ᵃ⤻ᶻ “KI Gadgets”

Bestseller No. 3 ᵃ⤻ᶻ “KI Gadgets”

Bestseller No. 4 ᵃ⤻ᶻ «KI Gadgets»

Bestseller No. 5 ᵃ⤻ᶻ “KI Gadgets”

Did you like the article or the news - Shortages of children's medicines in Germany: A mixed outcome? Then subscribe to us on Insta: AI News, Tech Trends & Robotics - Instagram - Boltwise

Our KI morning newsletter “The KI News Espresso” with the best AI news of the last day free by email – without advertising: Register here for free!




Shortages of children's medicines in Germany: A mixed outcome
Shortages of children’s medicines in Germany: A mixed outcome (Photo: DALL-E, IT BOLTWISE)

Please send any additions and information to the editorial team by email to de-info[at]it-boltwise.de. Since we cannot rule out AI hallucinations, which rarely occur with AI-generated news and content, we ask you to contact us via email and inform us in the event of false statements or misinformation. Please don’t forget to include the article headline in the email: “Shortages of children’s medicines in Germany: A mixed outcome”.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *